VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

A. N. J. Tutt, J. Garber,R. D. Gelber,K-A Phillips, A. Eisen,O. T. Johannsson,P. Rastogi,K. Y. Cui,S-A Im, R. Yerushalmi,A. M. Brufsky,M. Taboada, G. Rossi,G. Yothers, C. Singer, L. E. Fein,N. Loman,D. Cameron,C. Campbell, C. E. Geyer

Annals of Oncology(2022)

引用 29|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要